Mesenchymal stromal cells and alpha-1 antitrypsin have a strong synergy in modulating inflammation
Trauma, surgery, and infection can cause severe inflammation. Both dysregulated inflammation intensity and duration can lead to significant tissue injuries, organ dysfunction, mortality, and morbidity. Anti-inflammatory drugs such as steroids and immunosuppressants can dampen inflammation intensity, but they derail inflammation resolution, compromise normal immunity, and have significant adverse effects. The natural inflammation regulator mesenchymal stromal cells (MSCs) have high therapeutic potential because of their unique capabilities to mitigate inflammation intensity, enhance normal immunity, and accelerate inflammation resolution and tissue healing. Furthermore, clinical studies have shown that MSCs are safe and effective. However, they are not potent enough, alone, to completely resolve severe inflammation and injuries. One approach to boost the potency of MSCs is to combine them with synergistic agents. We hypothesized that alpha-1 antitrypsin (A1AT), a plasma protein used clinically and having an excellent safety profile, was a promising candidate for synergism. This investigation examined the efficacy and synergy of MSCs and A1AT to mitigate inflammation and to promote resolution, using in vitro cell cultures and a mouse acute lung injury and inflammation model. We found that the combination of MSCs and A1AT was much more effective than each component alone in i) modulating cytokine releases and inflammatory pathways, ii) inhibiting reactive oxygen species (ROS) and neutrophil extracellular traps (NETs) production by neutrophils, iii) enhancing phagocytosis and, iv) promoting inflammation resolution, tissue healing, and animal survival. Our results support the combined use of MSCs and A1AT for managing severe, acute inflammation.